UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
Table 1
Baseline characteristics of 17 patients with BRAF-mutated mCRC stratified by tumor sidedness.
Characteristic
All patients (N = 17)
Group A (right side) (N = 9)
Group B (left side) (N = 8)
value
Age (years)
Median ± SDa (range)
58 ± 12.9 (35–81)
58 ± 10.8 (36–73)
53.5 ± 15.8 (35–81)
1.000
Gender
0.109
Male
8 (47.1%)
6 (66.7%)
2 (25%)
Female
9 (52.9%)
3 (33.3%)
6 (75%)
Histology
1.000
WD
0 (0%)
0 (0%)
0 (0%)
MD
13 (76.5%)
7 (77.8%)
6 (75%)
PD
4 (23.5%)
2 (22.2%)
2 (25%)
Site of metastasis
0.580
1
6 (35.3%)
3 (33.3%)
3 (37.5%)
2
7 (41.2%)
3 (33.3%)
4 (50.0%)
≥3
4 (23.5%)
3 (33.3%)
1 (12.5%)
BMI (kg/m2)
0.871
Mean ± SDa
24.4 ± 2.48
23.4 ± 2.98
23.1 ± 6.44
UGT1A1
0.735
∗1/∗1
15 (88.2%)
8 (88.9%)
7 (87.5%)
∗1/∗28
2 (11.8%)
1 (11.1%)
1 (12.5%)
Response
0.067
Complete response
0 (0.0%)
0 (0%)
0 (0%)
Partial response
2 (11.8%)
0 (0%)
2 (25.0%)
Stable disease
9 (52.9%)
7 (77.8%)
2 (25.0%)
Progressive disease
6 (35.3%)
2 (22.2%)
4 (50.0%)
Responder
0.11
Yes
2 (11.8%)
0 (0%)
2 (25%)
No
15 (89.2%)
9 (100%)
6 (75%)
DCR
0.23
Yes
11 (64.7%)
7 (77.8%)
4 (50%)
No
6 (35.3%)
2 (22.2%)
4 (50%)
WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated; DCR: disease control rate.
